Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.7.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash flows from operating activities:    
Net loss $ (30,995) $ (11,978)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 25,730 22,199
Non-cash interest 640 749
Amortization of deferred financing costs 56 37
Losses from investments in investees 2,131 2,345
Equity-based compensation – employees and non-employees 9,693 17,307
Realized loss (gain) on equity securities and disposal of fixed assets (2,997) 0
Change in fair value of derivative instruments (4,037) 1,423
Change in fair value of contingent consideration 2,371 1,753
Deferred income tax benefit (9,236) (22,244)
Changes in assets and liabilities, net of the effects of acquisitions:    
Accounts receivable, net (17,771) (9,924)
Inventory, net (50) (152)
Other current assets and prepaid expenses 4,692 (6,883)
Other assets (235) 1,447
Accounts payable 19,539 (349)
Foreign currency measurement (69) (253)
Deferred revenue (17,357) (17,809)
Accrued expenses and other liabilities (16,024) 13,126
Net cash used in operating activities (33,919) (9,206)
Cash flows from investing activities:    
Investments in investees 0 (250)
Purchase of marketable securities 0 0
Proceeds from the sale of property, plant and equipment 3,095 0
Capital expenditures (9,537) (9,812)
Net cash used in investing activities (6,442) (10,062)
Cash flows from financing activities:    
Proceeds from the exercise of Common Stock options and warrants 1,866 2,154
Borrowings on lines of credit 7,825 5,248
Repayments of lines of credit (7,517) (7,349)
Net cash provided by financing activities 2,174 53
Effect of exchange rate changes on cash and cash equivalents 506 590
Net decrease in cash and cash equivalents (37,681) (18,625)
Cash and cash equivalents at beginning of period 168,733 193,598
Cash and cash equivalents at end of period 131,052 174,973
SUPPLEMENTAL INFORMATION:    
Interest paid 550 623
Income taxes paid, net 848 1,505
Shares issued upon the conversion of:    
Common Stock options and warrants, surrendered in net exercise 696 35
OPKO Health Europe    
Issuance of capital stock to acquire or contingent consideration settlement:    
Capital stock issued $ 0 $ 313